• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Predictive Oncology Inc.

    6/2/25 4:16:45 PM ET
    $POAI
    Industrial Specialties
    Health Care
    Get the next $POAI alert in real time by email
    424B5 1 f424b5_053025.htm 424B5

    As Filed Pursuant to Rule 424(b)(5)

    Registration No. 333-279123

    PROSPECTUS SUPPLEMENT

    To Prospectus Supplement dated April 18, 2025

    (To Prospectus and Prospectus Supplement dated May 21, 2024)

     

     

    Up to $3,398,000

    Common Stock

     

    This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus supplement, dated April 18, 2025, to the prospectus, dated May 21, 2024, filed with the Securities and Exchange Commission as part of our registration statement on Form S-3 (333-279123), as supplemented by our prospectus supplement, dated May 21, 2024 (collectively, the “ATM Prospectus”), relating to the offer and sale of shares of our common stock from time to time pursuant to the terms of the ATM Sales Agreement, dated May 3, 2024 (the “Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”) as sales agent. During the twelve calendar months prior to, and including, the date hereof, we have sold an aggregate of 121,792 shares of our common stock for aggregate gross proceeds of approximately $139,463 through Wainwright under the Agreement. This Prospectus Supplement should be read in conjunction with the ATM Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus, and any future amendments or supplements thereto.

     

    As of the date of this Prospectus Supplement, the aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $12,248,137, which was calculated based on 8,940,246 shares of our outstanding common stock held by non-affiliates and a price of $1.37 per share, the closing price of our common stock on April 3, 2025, which is the highest closing sale price of our common stock on the Nasdaq Capital Market within the prior 60 days. As of the date of this Prospectus Supplement, we have sold securities with an aggregate market value of approximately $684,467 pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this Prospectus Supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6) in any 12 calendar month period so long as our public float remains below $75.0 million.

     

    We are filing this Prospectus Supplement to amend the ATM Prospectus to update the maximum amount of shares that we are eligible to sell from and after the date hereof, and to specify the value of common stock we would be permitted to sell in any 12 calendar month period under General Instruction I.B.6. We may currently only offer and sell shares of our common stock having an aggregate offering price of up to $3,398,000 pursuant to this Prospectus Supplement in accordance with the terms of the Agreement, and as a result of the limitations set forth in General Instruction I.B.6. However, in the event that our public float increases or decreases, we may sell securities in public primary offerings on Form S-3 with a value up to one-third of our public float, in each case calculated pursuant to General Instruction I.B.6 and subject to the terms of the Agreement. In the event that our public float increases above $75.0 million, we will no longer be subject to the limits in General Instruction I.B.6 of Form S-3. If our public float increases such that we may sell additional amounts under the Agreement and the registration statement of which this Prospectus Supplement and the ATM Prospectus are a part, we will file another prospectus supplement prior to making additional sales. 

     

     

     

     

    Our common stock trades on the Nasdaq Capital Market under the symbol “POAI.” On May 30, 2025, the last reported sale price of our common stock on the Nasdaq Capital Market was $0.8801 per share.

     

    INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE “RISK FACTORS” ON PAGE S-9 OF THE ATM PROSPECTUS AND IN THE DOCUMENTS INCORPORATED BY REFERENCE IN THE REGISTRATION STATEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

     

    H.C. Wainwright & Co.

     

    The date of this prospectus supplement is June 2, 2025.

     

     

     

     

     

     

     

     

     

     

    Get the next $POAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POAI

    DatePrice TargetRatingAnalyst
    8/19/2024$3.00Buy
    H.C. Wainwright
    6/30/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $POAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

    PITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today announced that on December 1, 2025, the Company received a notification letter from Nasdaq notifying the Company that it regained compliance with Nasdaq's minimum stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. As a result, the Company's shares will continue to trade on the Nasdaq Capital Market under the ticker "POAI."

    12/2/25 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

    PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights: Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of lo

    11/14/25 5:12:46 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

    Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of

    10/14/25 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Vennare Raymond F covered exercise/tax liability with 2,373 shares, decreasing direct ownership by 27% to 6,418 units (SEC Form 4)

    4 - Predictive Oncology Inc. (0001446159) (Issuer)

    12/2/25 6:03:38 PM ET
    $POAI
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Matthews Shawn

    3 - Predictive Oncology Inc. (0001446159) (Issuer)

    10/17/25 5:01:41 PM ET
    $POAI
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Mclaughlin Thomas Louis

    3 - Predictive Oncology Inc. (0001446159) (Issuer)

    10/17/25 5:01:08 PM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Predictive Oncology with a new price target

    H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

    8/19/24 6:55:24 AM ET
    $POAI
    Industrial Specialties
    Health Care

    HC Wainwright & Co. initiated coverage on Predictive Oncology with a new price target

    HC Wainwright & Co. initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $5.00

    6/30/21 6:22:58 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Litchfield Hills Research initiated coverage on Predictive Oncology with a new price target

    Litchfield Hills Research initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

    2/1/21 10:17:27 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    SEC Filings

    View All

    SEC Form S-8 filed by Predictive Oncology Inc.

    S-8 - Axe Compute Inc. (0001446159) (Filer)

    12/12/25 5:24:24 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Axe Compute Inc. (0001446159) (Filer)

    12/12/25 5:17:43 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Predictive Oncology Inc. (0001446159) (Filer)

    12/2/25 5:15:28 PM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Leadership Updates

    Live Leadership Updates

    View All

    Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

    Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of

    10/14/25 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    AIRNA Appoints Matthew Hawryluk as Chief Business Officer

    AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a proven track record of bridging scientific innovation and commercial application. "Matt is a tremendous addition to our leadership team, bringing extensive experience driving collaborations and leading high-performing teams," said Kris Elverum, President and CEO of AIRNA. "Matt joins us at a critical time, as we prepare to bring our first RNA editing therapeutic to the clinic. We have the pote

    1/30/25 7:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Renovaro Issues Shareholder Letter and Provides Corporate Update

    Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive analysis of both businesses and development of a 100-day plan of action has already turned up some hidden value in both businesses and is helping us understand key areas of the business we need to for

    1/7/25 9:15:00 AM ET
    $POAI
    $RENB
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $POAI
    Financials

    Live finance-specific insights

    View All

    Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

    PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights: Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of lo

    11/14/25 5:12:46 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

    PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i

    11/13/24 7:00:21 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

    PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2024, and provided a corporate update. The Company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. Q2 2024 and Recent Highlights: Entered biomarker discovery market following compelling results from retrospective ovarian cancer s

    8/14/24 7:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Predictive Oncology Inc. (Amendment)

    SC 13G/A - Predictive Oncology Inc. (0001446159) (Subject)

    2/11/22 7:50:59 AM ET
    $POAI
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed

    SC 13G - Predictive Oncology Inc. (0001446159) (Subject)

    3/1/21 6:23:16 AM ET
    $POAI
    Industrial Specialties
    Health Care